Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX vaccine in AML
NCT00116467Phase 2Completed
- Sponsor
- Cell Genesys
- Start
- Mar 2001
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GVAX pancreatic cancer vaccine in acute myeloid leukemia (AML), sponsored by Cell Genesys. Primary endpoints: Clinical and laboratory safety and Feasibility of generation of GVAX leukemia vaccine. Started Mar 2001; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00116467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116467.